Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,849 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Standard care alone Clear all

Conditions: Muscle Invasive Bladder Cancer
Interventions: Durvalumab, Tremelimumab, Enfortumab Vedotin, Radical Cystectomy; Drug · Procedure
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 712 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 31
States / cities: Orange, California • Santa Monica, California • New Haven, Connecticut + 28 more

Conditions: Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer, Head and Neck Cancer, Lung Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, UC (Urothelial Cancer), Mesothelioma
Interventions: INCB001158, Pembrolizumab; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 13
States / cities: Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 7 more

Conditions: HIV Infection, Advanced End Stage Heart Failure
Interventions: HIV-positive heart transplant; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions: R-DXd, Bevacizumab, Carboplatin, Paclitaxel, Gemcitabine, Pegylated liposomal doxorubicin (PLD); Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 4
States / cities: Fountain Valley, California • Orlando, Florida • Burlington, Massachusetts + 1 more

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma, Oligometastatic Breast Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment, Computed Tomography, Cyclin-Dependent Kinase 4 Inhibitor, Cyclin-Dependent Kinase 6 Inhibitor, Echocardiography Test, HER2-targeted Therapy, Hormone Therapy, Magnetic Resonance Imaging, Mammography, Pertuzumab, Positron Emission Tomography, Radiation Boost, Radiation Therapy, Stereotactic Body Radiation Therapy, Stereotactic Radiosurgery, Taxane Compound, Total Mastectomy, Trastuzumab, Trastuzumab Deruxtecan, Trastuzumab Emtansine, Ultrasound Imaging; Procedure · Drug · Biological + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 562 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2033
U.S. locations: 59
States / cities: Jonesboro, Arkansas • Derby, Connecticut • Fairfield, Connecticut + 45 more

Conditions: Generalized Myasthenia Gravis, gMG
Interventions: Oral Corticosteroid Tapering Schedule, Ravulizumab, Prednisone/Prednisolone; Procedure · Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Chicago, Illinois • Schaumburg, Illinois • Neptune City, New Jersey + 2 more

Conditions: Acute Lymphoblastic Leukemia
Interventions: Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy), Calaspargase Pegol, Rituximab; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years to 50 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: High-Risk Multidisciplinary Care, Clinical Decision Support, Artificial Intelligence-Assisted Care, Telemedicine
Interventions: Gemini 3.1 Pro with Safety Prompt, ANCHOR Clinical AI Verification Layer (with Gemini 3.1 Pro); Behavioral
Lead sponsor: Waymark; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Neonatal Abstinence Syndrome, Aromatherapy
Interventions: lavender and chamomile essential oils; Drug
Lead sponsor: John M. Daniel; Other
Eligibility: Up to 2 Weeks
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Spasticity as Sequela of Stroke, Spastic Cerebral Palsy, Spasticity, Muscle
Interventions: stereotactic radiosurgery (SRS) dorsal root rhizotomy radiomodulation, Sham; Radiation · Other
Lead sponsor: Ohio State University; Other
Eligibility: 16 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Winter Park, Florida • Columbus, Ohio

Conditions: Surgery, Otolaryngologic Disorder, Pain, Postoperative
Interventions: Virtual Reality, Fitbit; Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Colorectal Tumors, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Adenocarcinoma, Colorectal Cancer
Interventions: Avelumab, Ad-CEA vaccine, Bevacizumab, 5-Fluorouracil (FU), Leucovorin, Oxaliplatin, Capecitabine; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: End-stage Kidney Disease
Interventions: Inform Me: web-based education tool; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 21 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Birmingham, Alabama • Chicago, Illinois

Conditions: Lung Cancer
Interventions: Aerobic Training, Progressive Stretching, Resistance Training, Aerobic and Resistance Training; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Obesity, Morbid, Hypertension, Bariatric Surgery Candidate
Interventions: Antibiotic; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Cancer
Interventions: Pre-Test Intervention, Standard of Care, Post-Test Intervention; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Kidney Transplantation
Interventions: Arm 1: SOC (mTOR + CNI), Arm 2A: TRACT/MONO mTOR, Arm 2B: TRACT/MONO CNI; Drug · Biological
Lead sponsor: Singulera Therapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 3
States / cities: Phoenix, Arizona • Chicago, Illinois • Rochester, Minnesota

Conditions: Prostate Adenocarcinoma
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Enzalutamide, Fluorine F 18 Piflufolastat, Image Guided Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Relugolix; Procedure · Drug · Other + 1 more
Lead sponsor: Sean Sachdev; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Persistent Atrial Fibrillation
Interventions: Scar-Based Radio-frequency Ablation, Rotor Anchors Radio-frequency Ablation, Conventional PVI by Radio-frequency Ablation; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: CVA, Gait, Hemiplegic
Interventions: EksoGT™, Ekso Bionics, Berkley, CA, USA, Standard of Care, No Intervention; Device · Other
Lead sponsor: Kessler Foundation; Other
Eligibility: 21 Years to 80 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Malignancy, Metastasis, Hemoptysis, Gastrointestinal Bleeding, Pelvic Bleeding, Superior Vena Cava Syndrome, Mediastinal Disease
Interventions: Volumetric MR imaging, Radiation therapy; Device · Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Aging, Fall Injury
Interventions: Medication Action Plan and Patient Empowerment (MAP-PE ); Behavioral
Lead sponsor: University of Iowa; Other
Eligibility: 60 Years to 110 Years
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Clive, Iowa

Conditions: Heart Failure, Systolic, Left Ventricular Assist Device, ICD
Interventions: ICD programming; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions: geriatric assessment and telephone call from nurse, geriatric assessment and no call from nurse; Behavioral · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 65 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2025
U.S. locations: 3
States / cities: Commack, New York • New York, New York

Search by objective public record fields.

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

HIV+ Deceased Donor Heart Transplant Study for HIV+ Recipients

A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)

Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab

CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

ANCHOR Validation Trial in High-Risk Multidisciplinary Care

The Effect of Aromatherapy on Neonatal Abstinence Syndrome and Salivary Cortisol Levels

Radiosurgery Treatment for Spasticity Associated With Stroke, SCI & Cerebral Palsy

Digital Intervention Postoperative Protocol

Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004

Optimizing Kidney Transplant Informed Consent

Lung Cancer Exercise Training Study

Antibiotics, Gastric Bypass, and the Microbiome

Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer Patients

REgulatory T Cell Therapy to Achieve Immunosuppression REduction

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

The Substrate and Intervention Mechanisms for Persistent Atrial Fibrillation Trial

Robotic Exoskeleton Assisted Gait Post Stroke

Same-session MR-only Simulation and Treatment With MRI-guided Adaptive Palliative RadioTherapy

Medication Empowerment and Deprescription for Safety (MEDS) Study

STandardized Ultra-conservative Or Physician-directed ICD Programming for Continuous Flow LVAD Support

Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian Cancer